Table 1.
Characteristics of all PCNSL patients
| Characteristics | Total (N = 35) | Included in gene analysis (N = 21) | Comparison between total population and subgroup p value |
|---|---|---|---|
| Median age (range) | 62 (26–84) | 68 (26–84) | .493 |
| > 60 years | 19 (54.3) | 14 (66.7) | .412 |
| Gender | |||
| Female | 20 (57.1%) | 13 (61.9%) | .785* |
| Male | 15 (42.9%) | 8 (38.1%) | |
| IELSG prognostic score | |||
| Low risk (0 + 1) | 7 (20%) | 2 (9.5%) | .572* |
| Intermediate risk (2 + 3) | 17 (48.6%) | 10 (47.6%) | |
| High risk (4 + 5) | 11 (31.4%) | 9 (42.9%) | |
| ECOG | |||
| ≤2 | 20 (57.1%) | 10 (47.6%) | .584* |
| >2 | 15 (42.9%) | 11 (52.4) | |
| Deep CNS involvement a | |||
| Yes | 27 (77.1%) | 18 (85.7%) | .508* |
| No | 8 (22.9%) | 3 (14.3%) | |
| Treatment based on HDMTX b | |||
| No | 5 (15.2%) | 3 (15.8%) | 1* |
| Yes | 28 (84.8%) | 16 (84.2%) | |
| Response type after 1st line c | |||
| CR | 15 (45.5%) | 7 (36.8%) | .715* |
| PR | 9 (27.3%) | 7 (36.8%) | |
| Progression disease | 9 (27.3%) | 5 (26.3%) | |
| WBRT d , e | |||
| No | 14 (40%) | 7 (33.4%) | .777* |
| Yes | 21 (60%) | 14 (66.6%) | |
| Relapse after 1st line f | |||
| No | 12 (80%) | 5 (71.4%) | 1* |
| Yes | 3 (20%) | 2 (28.6%) | |
| Refractory disease g | |||
| No | 24 (72.7%) | 14 (73.7%) | 1* |
| Yes | 9 (27.3%) | 5 (26.3%) | |
| Death cause h | |||
| Progression disease | 21 (80.7%) | 12 (80%) | 1* |
| Other | 5 (19.3%) | 3 (20%) | |
Data are presented as n (%) or median (range).
Abbreviations: CNS, central nervous system; CR, complete response; ECOG, Eastern Cooperative Oncology Group; HDMTX, high‐dose methotrexate induction chemotherapy; IELSG, International Extranodal Lymphoma Study Group; Modified IPI, Modified International Prognostic Index; PR, partial response; WBRT, whole‐brain radiotherapy.
Deep nervous system involvement is characterized by periventricular regions, basal ganglia, brainstem, and/or cerebellum.
Percentage calculated among patients who received at least 1 line of therapy and who were treated with HDMTX.
Percentage calculated among patients who received at least 1 line of therapy.
WBRT 40 grays in 20 fractions was prescribed either as consolidation treatment or as monotherapy for patients who did not tolerate chemotherapy or after progression.
Percentage calculated among patients treated with WBRT.
Percentage calculated among patients who achieved CR after 1st line.
Percentage calculated among patients who received at least 1 line of therapy.
Percentage calculated among patients who died.
Student's t test; **Independent t test.